Oncolytic viruses as therapeutic agents

Annals of Medicine

Volumn 33, Issue 5, 2001, Pages 291-304

  Wildner, O ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Conditionally replicating viruses; Gene therapy; Oncolysis; Virotherapy

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; GENE TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS; IMMUNE SYSTEM; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PARVOVIRUS; POLIOMYELITIS VIRUS; POXVIRUS; PRIORITY JOURNAL; PROMOTER REGION; REOVIRUS; REVIEW; SUICIDE GENE; TRANSGENE; TUMOR CELL DESTRUCTION; VESICULAR STOMATITIS VIRUS; VIRUS CAPSID; VIRUS REPLICATION;

EID: 0034924357     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890109002081     Document Type: Review

References (143)

1. Sulla scomparsa di un enorme cancro vegetante del callo dell'utero senza cura chirurgica
2. Viruses in the treatment of cancer
3. Studies on the use of viruses in the treatment of carcinoma of the cervix
4. Treatment of human cancer with mumps virus
5. Measles and leukaemia
6. Viruses as an aid to cancer therapy: Regression of solid and ascites tumors in rodents after treatment with bovine enterovirus
7. Newcastle disease virus selectively kills human tumor cells
8. Newcastle disease virus as an antineoplastic agent
9. Newcastle disease virus as an antineoplastic agent: Induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity
10. A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate
11. Clinical studies of viruses as antineoplastic agents, with particular reference to Egypt 101 virus
12. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate
13. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir
14. Experimental therapy of human glioma by means of a genetically engineered virus mutant
15. West Nile, Ilhéus and Bunyamwera virus infection in man
16. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
17. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double-suicide gene, and radiotherapy
18. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of HSV-tk
19. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas
20. The role of the E1B 55 kDa gene in oncolytic adenoviral vectors expressing HSV-tk: Assessment of anti-tumor efficacy and toxicity
21. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
22. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
23. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts
24. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
25. Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector
26. Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy
27. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant
28. Herpes simplex 1716 - An ICP 34.5 mutant - Is severely replication restricted in human skin xenografts in vivo
29. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
30. Reovirus therapy of tumors with activated Ras pathway
31. Antineoplastic activity of parvoviruses
32. Newcastle disease virus as an antineoplastic agent
33. Attenuated veterinary virus vaccine for the treatment of cancer
34. Poxvirus vectors: Orphaned and underappreciated
35. Intergeneric poliovirus recombinants for the treatment of malignant glioma
36. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
37. Adenoviridea
38. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5
39. Terminally differentiated skeletal myotubes are not confined to G0 but can enter G1 upon growth factor stimulation
40. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein
41. Dissection of functional domains in the adenovirus 2 early 1B 55K polypeptide by suppressor-linker insertional mutagenesis
42. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
43. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
44. p53-dependent cell death/apoptosis is required for a productive adenovirus infection
45. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
46. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection
47. Trans E1 component requirements for maximal replication of E1-defective recombinant adenovirus
48. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status
49. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication
50. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: The importance of the adenoviral E1b-55kD gene
51. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma
52. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk
53. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses
54. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle
55. Adenovirus type 5 early region 1b gene product is required for efficient shutoff of host protein synthesis
56. Interaction of adenoviral E4 and E1b products in late gene expression
57. Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff
58. The adenovirus E1B 55 kd protein influences mRNA transport via an intranuclear effect on RNA metabolism
59. The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs
60. Host-range mutants of adenovirus type 5 defective for growth in HeLa cells
61. Isolation of type 5 adenovirus mutants with a cold-sensitive host range phenotype: Genetic evidence of an adenovirus transformation maintenance function
62. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
63. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: Evidence for reduced toxicity and enhanced antitumor activity in mice
64. Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways
65. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy
66. Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action
67. Cytogenetic genotoxicity of antiherpes virostatics in Chinese hamster V79-E cells. I. Purine nucleoside analogues
68. Comparative in-vivo genotoxicity of antiviral nucleoside analogues; penciclovir, acyclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay
69. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
70. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
71. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer
72. Subcutaneous administration of a replication-competent adenovirus expressing HSV-tk to cotton rats: Dissemination, persistence, shedding, and pathogenicity
73. Complementary adenoviral vectors for oncolysis
74. The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors
75. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture
76. Herpes simplex viruses
77. Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1
78. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption
79. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant
80. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
81. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors
82. Differentiation of the shutoff of protein synthesis by virion host shutoff and mutant gamma (1)34.5 genes of herpes simplex virus 1
83. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the "a" sequence
84. The JH2604 deletion variant of herpes simplex virus type 2 (HG52) fails to produce necrotizing encephalitis following intracranial inoculation of mice
85. The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice
86. ICP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro
87. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
88. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
89. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors
90. Disabled infectious single cycle (DISC) herpes simplex virus as a vector for immunotherapy of cancer
91. A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells
92. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1
93. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207
94. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207)
95. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy
96. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma
97. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant
98. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy
99. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma
100. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies
101. Reoviruses: A new group of respiratory and enteric viruses formerly calssified as ECHO type 10 is described
102. Reoviruses and their replication
103. Viruses causing common respiratory infection in man. IV. Reoviruses and adenoviruses
104. Differential sensitivity of normal and transformed human cells to reovirus infection
105. The preferential cytotoxicity of reovirus for certain transformed cell lines
106. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus
107. Reovirus-induced apoptosis is mediated by TRAIL
108. Ras oncogenes in human cancer: A review
109. Parvoviridae: The viruses and their replication
110. Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells
111. Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector
112. Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding non-structural proteins
113. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells
114. Induction of programmed cell death by parvovirus H-1 in U937 cells: Connection with the tumor necrosis factor alpha signaling pathway
115. Antineoplastic activity of parvoviruses
116. Upstream CREs participate in the basal activity of minute virus of mice promoter P4 and in its stimulation in ras-transformed cells
117. Ras oncogene-dependent activation of the P4 promoter of minute virus of mice through a proximal P4 element interacting with the Ets family of transcription factors
118. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial
119. Immunization with virus-modified tumor cells
120. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants
121. A segment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation
122. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA
123. Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence
124. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
125. Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma
126. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
127. Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules
128. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
129. Development and mechanisms of interferon resistance
130. Rhabdovirus genomes and their products
131. Herpesviruses - Immune escape artists?
132. Viral escape from immune recognition: Multiple strategies of adenoviruses
133. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination
134. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector
135. Effect of prior exposure to herpes simplex virus 1 on viral vector- mediated tumor therapy in immunocompetent mice
136. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity
137. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus
138. Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis
139. Gene therapy for cancer: What have we done and where are we going?
140. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors
141. The effect of ganciclovir on herpes simplex virus-mediated oncolysis
142. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors
143. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy